stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Return on invested capital
Sarepta Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −2.03%, up 40.4 percentage points from fiscal 2025 (−42.5%). Over the past ten years it has ranged from −1,706.1% (fiscal 2015) to 10.4% (fiscal 2024); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −42.5% | (52.86) |
| FY2024 | 10.4% | 50.15 |
| FY2023 | −39.8% | (39.75) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 115.04 |
| FY2019 | −115.0% | (38.04) |
| FY2018 | −77.0% | (1.03) |
| FY2017 | −76.0% | 610.04 |
| FY2016 | −686.0% | 1,020.10 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 30.5% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. | −2.03% |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −13.6% |
| VIR Vir Biotechnology, Inc. compare | −30.3% |
| MAZE Maze Therapeutics, Inc. compare | −112.4% |
| REPL Replimune Group, Inc. compare | −928.3% |
| TRVI Trevi Therapeutics, Inc. compare | −1,412.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)